-
Aralast: A New α1-Protease Inhibitor for Treatment of α-Antitrypsin Deficiency
Program Information
Email to a Friend
Add to Cart 
Continue Shopping
| OBJECTIVE: To review the epidemiology, pathogenesis, and management of patients with α-antitrypsin (AAT) deficiency syndrome
and compare Aralast with Prolastin, 2 of the 3 available human plasma-derived AAT agents. DATA SOURCES: Articles were identified using a MEDLINE (1966-September 2005) search with MESH headings that included α-antitrypsin and emphysema. STUDY SELECTION AND DATA EXTRACTION: All papers from peer-reviewed journals on the laboratory or clinical efficacy of plasma-derived AAT (eg, Prolastin, Aralast) for patients with this autosomal recessive disorder were reviewed. DATA SYNTHESIS: Clinical trials found that AAT augmentation prevents progression of AAT-deficient emphysema and thus its associated morbidity and mortality. Treatment with Aralast has been shown to be safe and well tolerated, with a low incidence of mild to moderate adverse events. Pharmacoeconomics studies of AAT augmentation demonstrated that the use of Aralast was cost-effective as lifelong augmentation therapy for AAT-deficient emphysema. CONCLUSIONS: Because of its effectiveness and extra safety measure compared with Prolastin, Aralast should be recommended for formulary inclusion. Key Words: α-antitrypsin: Aralast, Prolastin; emphysema Published Online, October 11, 2005. www.theannals.com, DOI 10.1345/aph.1E061 THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT ACPE UNIVERSAL PROGRAM NUMBER: 407-000-05-033-H01 |
PharmaCETM
is a service of HARVEY WHITNEY BOOKS COMPANY
8044 Montgomery Road, Suite 415, Cincinnati, OH 45236-2919
P.O. Box 42696, Cincinnati, OH 45242-0696 USA
Toll Free: 877/742-7631
Tel. 513/793-3555, FAX 513/793-3600
Office Hours: Monday - Friday 9-5 E.S.T.
Contact Us
All Rights Reserved. Copyright © 1998-